Melanotan II vs PT-141: why the FDA approval difference matters

Same lab, same molecule family. Very different paperwork — and very different patient stakes.

TL;DR

• PT-141 (bremelanotide) is FDA-approved as the finished drug Vyleesi for hypoactive sexual desire disorder in premenopausal women. The compounded version used outside the Vyleesi label is not itself FDA-approved.
• Melanotan II is not FDA-approved for anything. The FDA has issued public warnings about it.
• Both came from the same melanocortin research, but they hit different receptors and carry very different safety records.

What it is

Both PT-141 and Melanotan II grew out of melanocortin research at the University of Arizona in the 1990s. The melanocortin system (in plain English: a family of brain and skin signals that regulate pigmentation, appetite, and arousal) has five receptors. PT-141 and Melanotan II hit overlapping but different ones — and that difference is the whole story.

PT-141, also called bremelanotide, is FDA-approved as Vyleesi for HSDD (hypoactive sexual desire disorder — persistent low desire that causes distress) in premenopausal women (FDA Vyleesi label, 2019). The compounded peptide-protocol version of PT-141 used outside the Vyleesi label is not itself FDA-approved as a finished drug. Melanotan II is sold online as a "tanning peptide" but is not FDA-approved for any use and has no published Phase 3 safety package.

How it works

Think of melanocortin receptors as five switchboards. MC1R handles skin pigmentation. MC2R handles the stress hormone pathway. MC3R and MC4R sit on appetite and arousal. MC5R covers other roles. PT-141 favors MC3R and MC4R. That is why Vyleesi's FDA-approved indication is sexual desire (the compounded version is not itself FDA-approved). Melanotan II hits MC1R more strongly. That is why people use it for tanning. And that same MC1R activity drives reports of new moles, atypical pigmentation, and the FDA's safety warnings (Habbema et al., 2017).

Who asks about it

People come to this topic when they see both names in the same forum thread and assume they are interchangeable. They are not. One is a prescription drug with a published safety package. The other is a gray-market powder with public FDA warnings.

What the research says

PT-141 has Phase 3 trial data behind its HSDD indication. Bremelanotide is also studied for arousal disorders in men, but most published work is in women. Melanotan II's published literature is older, smaller, and focuses on pigmentation; it has not gone through a modern Phase 3 safety package for any use.

What to know before considering it

Both are injectables. Both can cause nausea, flushing, and injection-site reactions. Melanotan II carries additional reported concerns including new or atypical moles and rare cases of priapism. PT-141 should only be used under physician supervision and is contraindicated in uncontrolled hypertension.

The Halftime POV

The regulatory paperwork is not bureaucratic noise — it is the difference between a drug with a known safety profile and a powder with public FDA warnings. We work only with peptides accessible through licensed physicians and state-licensed 503A compounding pharmacies.

Related reading:

• PT-141 for women: what the bremelanotide research shows for female desire
• Erectile dysfunction as a vascular health signal

---

FAQ

Q: Is melanotan-2 the same as PT-141? A: No. They are related molecules from the same research family, but they are different drugs with different receptor activity and a very different regulatory status.

Q: Is melanotan-2 FDA-approved? A: No. Melanotan-2 is not FDA-approved for any use. The FDA has issued public warnings about products sold as melanotan-2.

Q: Is PT-141 FDA-approved? A: Yes. PT-141 is the active ingredient in Vyleesi (bremelanotide), an FDA-approved injectable for hypoactive sexual desire disorder in premenopausal women. The compounded version used in some peptide protocols is not itself FDA-approved as a finished drug.

Q: Why are people still buying melanotan-2 online? A: Online sellers often market melanotan-2 as a tanning peptide, despite FDA warnings about safety and quality. Most products sold this way are research-use-only powders sold outside the legal pharmacy system.

---

Disclaimer

As of May 2026, Melanotan II is classified by the FDA as Category 2, which means it is not available from 503A compounding pharmacies. A February 2026 HHS announcement proposed returning several peptides to Category 1 pending formal FDA Federal Register notice; Melanotan II's status remains restricted. This article is educational and is not medical advice. Halftime Health only prescribes through licensed clinicians in states where our partner physicians are credentialed.

Get updates

Halftime Health is launching soon. We'll share what we learn along the way — the research, the regulations, the real-world trade-offs. Join the waitlist and we'll email you when we're live.

---

Sources

• FDA Vyleesi (bremelanotide) prescribing information (2019)
• Habbema L et al., "Risks of unregulated use of alpha-melanocyte-stimulating hormone analogues: a review" (2017)

---

This article discusses compounds that are currently under FDA Category 2 review (see our FDA categorization explainer). These compounds are not currently part of Halftime Health's published protocol catalog. This article is provided for educational purposes only and does not constitute medical advice or an offer to sell.